These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
44. A pilot study of the role of intracavernous injection of vasoactive intestinal peptide (VIP) and phentolamine mesylate in the treatment of erectile dysfunction. McMahon CG Int J Impot Res; 1996 Dec; 8(4):233-6. PubMed ID: 8981173 [TBL] [Abstract][Full Text] [Related]
45. Compliance to longterm vasoactive intracavernous therapy. Pagliarulo A; Ludovico GM; Cirillo-Marucco E; Corvasce A; Pagliarulo G Int J Impot Res; 1996 Jun; 8(2):63-4. PubMed ID: 8858392 [TBL] [Abstract][Full Text] [Related]
46. [Clinical evaluation of intracavernous self-injection of vasoactive drugs for impotence: a long-term follow-up observation]. Hayashi S; Iwai Y; Yasumoto R; Matsuda J; Kawano M; Omachi T; Kono T; Yamamoto S; Sakakura T; Minami H Hinyokika Kiyo; 1994 Jan; 40(1):37-41. PubMed ID: 7509119 [TBL] [Abstract][Full Text] [Related]
48. Intracavernous sodium nitroprusside (SNP) versus papaverine/phentolamine in erectile dysfunction: a comparative study of short-term efficacy and side-effects. Tarhan F; Canguven O; Kuyumcuoglu U J Sex Med; 2006 Mar; 3(2):377. PubMed ID: 16490038 [No Abstract] [Full Text] [Related]
49. Treatment of prolonged or priapistic erections following intracavernosal papaverine therapy. Padma-Nathan H; Goldstein I; Krane RJ Semin Urol; 1986 Nov; 4(4):236-8. PubMed ID: 3797893 [No Abstract] [Full Text] [Related]
50. [Penile self-injection of a papaverine-phentolamine combination, as treatment of impotence, in patients treated with radical cystoprostatectomy]. Calahorra Fernández FJ; Rodríguez A; Castro M; Tamayo JC; Alvarez E; Leiva O Actas Urol Esp; 1991; 15(1):43-5. PubMed ID: 2058441 [TBL] [Abstract][Full Text] [Related]
51. [Prostaglandin E1 in erectile dysfunction]. Porst H Urologe A; 1989 Mar; 28(2):94-8. PubMed ID: 2655258 [TBL] [Abstract][Full Text] [Related]
53. Intracavernous injections for impotence. Med Lett Drugs Ther; 1990 Dec; 32(834):116-7. PubMed ID: 2255296 [No Abstract] [Full Text] [Related]
54. Intracavernous self-injection pharmacotherapy program: analysis of results and complications. Valdevenito R; Melman A Int J Impot Res; 1994 Jun; 6(2):81-91. PubMed ID: 7951702 [TBL] [Abstract][Full Text] [Related]
55. [Response to intracavernous administration of 3 different drugs in the same group of patients with erectile dysfunction]. Ribé N; Rajmil O; Bassas L; Jurado C; Pomerol JM Arch Esp Urol; 2001 May; 54(4):355-9. PubMed ID: 11455770 [TBL] [Abstract][Full Text] [Related]
56. [Papaverine-induced priapism. Experiences with a new urologic emergency]. Schneider AW; Busch R; Gonnermann D; Klosterhalfen H Dtsch Med Wochenschr; 1989 Feb; 114(6):214-7. PubMed ID: 2917481 [TBL] [Abstract][Full Text] [Related]
57. Prolonged erections following intracorporeal injection of medications to overcome impotence. Watters GR; Keogh EJ; Carati CJ; Earle CM; Wisniewski ZS; Tulloch AG; Lord DJ Br J Urol; 1988 Aug; 62(2):173-5. PubMed ID: 3408889 [TBL] [Abstract][Full Text] [Related]
58. A new method for the evaluation of erectile dysfunction: sildenafil plus Doppler ultrasonography. Arslan D; Esen AA; Seçil M; Aslan G; Celebi I; Dicle O J Urol; 2001 Jul; 166(1):181-4. PubMed ID: 11435852 [TBL] [Abstract][Full Text] [Related]
59. A comparative review of the options for treatment of erectile dysfunction: which treatment for which patient? Hatzimouratidis K; Hatzichristou DG Drugs; 2005; 65(12):1621-50. PubMed ID: 16060698 [TBL] [Abstract][Full Text] [Related]
60. Intracavernous alprostadil. A review of its pharmacodynamic and pharmacokinetic properties and therapeutic potential in erectile dysfunction. Lea AP; Bryson HM; Balfour JA Drugs Aging; 1996 Jan; 8(1):56-74. PubMed ID: 8785470 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]